{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/SION/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T19:44:37.774Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":5325,"canonical_name":"Sionna Therapeutics, Inc.","cik":"0002036042","uei":null,"lei":null,"duns":null,"ticker":"SION"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":35},"count":35,"timeline":[{"ts":"2026-09-18","kind":"sec.filing","form_type":"4","title":"4 — Sionna Therapeutics, Inc. — 2026-09-18","url_slug":"/sec/cik-0002036042/4/0002046433-26-000005","accession_number":"0002046433-26-000005","importance":30},{"ts":"2026-09-18","kind":"sec.filing","form_type":"4","title":"4 — Sionna Therapeutics, Inc. — 2026-09-18","url_slug":"/sec/cik-0002036042/4/0002061851-26-000009","accession_number":"0002061851-26-000009","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Sionna Therapeutics, Inc. — 2026-09-14","url_slug":"/sec/cik-0002036042/8-k/0001193125-26-390577","accession_number":"0001193125-26-390577","importance":35},{"ts":"2026-08-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Sionna Therapeutics, Inc. — 2026-08-10","url_slug":"/sec/cik-0002036042/8-k/0001193125-26-341230","accession_number":"0001193125-26-341230","importance":35},{"ts":"2026-08-06","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Sionna Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0002036042/10-q/0001628280-26-053839","accession_number":"0001628280-26-053839","importance":45},{"ts":"2026-08-06","kind":"sec.filing","form_type":"8-K","title":"8-K — Sionna Therapeutics, Inc. — 2026-08-06","url_slug":"/sec/cik-0002036042/8-k/0001628280-26-053832","accession_number":"0001628280-26-053832","importance":35},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":85918,"price_per_share":44.86,"usd_value":3854281,"security_title":"Common Stock","importance":38.85428148},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VIII LLC","title":"","shares":85918,"price_per_share":44.86,"usd_value":3854281,"security_title":"Common Stock","importance":38.85428148},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Thompson Peter A.","title":"","shares":85918,"price_per_share":44.86,"usd_value":3854281,"security_title":"Common Stock","importance":38.85428148},{"ts":"2026-07-07","kind":"sec.filing","form_type":"4","title":"4 — Sionna Therapeutics, Inc. — 2026-07-07","url_slug":"/sec/cik-0002036042/4/0002061851-26-000006","accession_number":"0002061851-26-000006","importance":30},{"ts":"2026-07-06","kind":"sec.form144","reporter":"JENNIFER FITZPATRICK","title":"Officer","shares":10250,"usd_value":450898,"security_title":"Common","approx_sale_date":"2026-07-06","accession_number":"0001950047-26-006887","importance":40.0901795},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Fitzpatrick Jennifer","title":"Chief Legal Officer","shares":10250,"price_per_share":43.5963,"usd_value":446862,"security_title":"Common Stock","importance":35.446862075},{"ts":"2026-07-06","kind":"sec.filing","form_type":"144","title":"144 — Sionna Therapeutics, Inc. — 2026-07-06","url_slug":"/sec/cik-0002036042/144/0001950047-26-006887","accession_number":"0001950047-26-006887","importance":30},{"ts":"2026-07-06","kind":"sec.insider.m","reporter":"Fitzpatrick Jennifer","title":"Chief Legal Officer","shares":10250,"price_per_share":6.11,"usd_value":62628,"security_title":"Common Stock","importance":15.0626275},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":115844,"price_per_share":45.5,"usd_value":5270902,"security_title":"Common Stock","importance":40.270902},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VIII LLC","title":"","shares":115844,"price_per_share":45.5,"usd_value":5270902,"security_title":"Common Stock","importance":40.270902},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Thompson Peter A.","title":"","shares":115844,"price_per_share":45.5,"usd_value":5270902,"security_title":"Common Stock","importance":40.270902},{"ts":"2026-06-18","kind":"sec.filing","form_type":"8-K","title":"8-K — Sionna Therapeutics, Inc. — 2026-06-18","url_slug":"/sec/cik-0002036042/8-k/0001628280-26-044263","accession_number":"0001628280-26-044263","importance":35},{"ts":"2026-06-18","kind":"sec.filing","form_type":"4","title":"4 — Ruddy Marcella K. — 2026-06-18","url_slug":"/sec/cik-0002023849/4/0002023849-26-000010","accession_number":"0002023849-26-000010","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"OrbiMed Private Investments VIII, LP","title":"Shareholder","shares":210876,"usd_value":9029710,"security_title":"Common Stock","approx_sale_date":"2026-05-29","accession_number":"0000947871-26-000589","importance":41.805942064},{"ts":"2026-05-12","kind":"sec.13dg","reporter":"Qatar Investment Authority","shares":2020258,"percent_of_class":4.5,"security_title":"SCHEDULE 13G/A","accession_number":"0001441449-26-000005","excerpt":null,"importance":55},{"ts":"2026-05-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Sionna Therapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0002036042/10-q/0001628280-26-033876","accession_number":"0001628280-26-033876","importance":45},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Sionna Therapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0002036042/8-k/0001628280-26-033870","accession_number":"0001628280-26-033870","importance":35},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"Thompson Peter A.","title":"","shares":184639,"price_per_share":46.22,"usd_value":8534015,"security_title":"Common Stock","importance":43.534014580000004},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":184639,"price_per_share":46.22,"usd_value":8534015,"security_title":"Common Stock","importance":43.534014580000004},{"ts":"2026-05-11","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VIII LLC","title":"","shares":184639,"price_per_share":46.22,"usd_value":8534015,"security_title":"Common Stock","importance":43.534014580000004},{"ts":"2026-05-08","kind":"sec.insider.s","reporter":"Thompson Peter A.","title":"","shares":59767,"price_per_share":44.58,"usd_value":2664413,"security_title":"Common Stock","importance":37.66441286},{"ts":"2026-05-08","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":59767,"price_per_share":44.58,"usd_value":2664413,"security_title":"Common Stock","importance":37.66441286},{"ts":"2026-05-08","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VIII LLC","title":"","shares":59767,"price_per_share":44.58,"usd_value":2664413,"security_title":"Common Stock","importance":37.66441286},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"Thompson Peter A.","title":"","shares":48546,"price_per_share":44.61,"usd_value":2165637,"security_title":"Common Stock","importance":37.16563706},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"ORBIMED ADVISORS LLC","title":"","shares":48546,"price_per_share":44.61,"usd_value":2165637,"security_title":"Common Stock","importance":37.16563706},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"OrbiMed Capital GP VIII LLC","title":"","shares":48546,"price_per_share":44.61,"usd_value":2165637,"security_title":"Common Stock","importance":37.16563706},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEF 14A","title":"DEF 14A — Sionna Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0002036042/def-14a/0001628280-26-027489","accession_number":"0001628280-26-027489","importance":40},{"ts":"2026-04-27","kind":"sec.filing","form_type":"ARS","title":"ARS — Sionna Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0002036042/ars/0001628280-26-027501","accession_number":"0001628280-26-027501","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Sionna Therapeutics, Inc. — 2026-04-27","url_slug":"/sec/cik-0002036042/defa14a/0001628280-26-027496","accession_number":"0001628280-26-027496","importance":30}]}